Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Opus Genetics (IRD) Total Non-Current Liabilities (2021 - 2024)

Opus Genetics (IRD) has disclosed Total Non-Current Liabilities for 8 consecutive years, with $3.8 million as the latest value for Q3 2023.

  • On a quarterly basis, Total Non-Current Liabilities rose 41.81% to $3.8 million in Q3 2023 year-over-year; TTM through Sep 2023 was $3.8 million, a 41.81% increase, with the full-year FY2022 number at $2.8 million, down 28.59% from a year prior.
  • Total Non-Current Liabilities was $3.8 million for Q3 2023 at Opus Genetics, down from $4.2 million in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $4.2 million in Q1 2023 to a low of $2.3 million in Q1 2021.
  • A 3-year average of $3.1 million and a median of $3.0 million in 2022 define the central range for Total Non-Current Liabilities.
  • Peak YoY movement for Total Non-Current Liabilities: dropped 28.59% in 2022, then skyrocketed 41.81% in 2023.
  • Opus Genetics' Total Non-Current Liabilities stood at $3.9 million in 2021, then decreased by 28.59% to $2.8 million in 2022, then skyrocketed by 38.61% to $3.8 million in 2023.
  • Per Business Quant, the three most recent readings for IRD's Total Non-Current Liabilities are $3.8 million (Q3 2023), $4.2 million (Q1 2023), and $2.8 million (Q4 2022).